Isobornylamin | 2223-67-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: Isobornylamin
• 英文别名: Exo-2-bornanamin；(1S,2S,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-amine
• CAS: 2223-67-8
• 化学式: C₁₀H₁₉N
• 分子量: 153.268
• InChiKey: MDFWXZBEVCOVIO-OYNCUSHFSA-N

物化性质

• 熔点：
  184°C
• 沸点：
  266.22°C (rough estimate)
• 密度：
  0.8498 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Isobornylamin 在 盐酸 作用下， 以 四氢呋喃 、 甲基叔丁基醚 为溶剂， 生成 (+/-)-Isobornylamin-hydrochlorid
  参考文献：
  名称：

  Potential Synthetic Adaptogens: V. Synthesis of Cage Monoamines by the Schwenk–Papa Reaction

  摘要：

  The reduction of cage ketoximes under Schwenk-Papa reaction conditions was studied to establish that the D,L, D- and L-camphor oximes are smoothly reduced to the corresponding amines in high yields. At the same time, D,L-norcamphor and adamantan-2-one oximes undergo partial catalytic deoximation to form a mixture of the corresponding amines and alcohols.

  DOI：

  10.1134/s1070428019110162
• 作为产物：
  描述：

  (+/-)-Isobornylamin-hydrochlorid 生成 Isobornylamin
  参考文献：
  名称：

  Potential Synthetic Adaptogens: V. Synthesis of Cage Monoamines by the Schwenk–Papa Reaction

  摘要：

  The reduction of cage ketoximes under Schwenk-Papa reaction conditions was studied to establish that the D,L, D- and L-camphor oximes are smoothly reduced to the corresponding amines in high yields. At the same time, D,L-norcamphor and adamantan-2-one oximes undergo partial catalytic deoximation to form a mixture of the corresponding amines and alcohols.

  DOI：

  10.1134/s1070428019110162

文献信息

• The endo- and exo-1,7,7-Trimethylbicyclo[2.2.1]heptan-2-amines (Bornan-2-amines) and their acetamides
  作者：RM Carman、KL Greenfield

  DOI：10.1071/ch9841785

  日期：——

  Melting points provide a poor method for differentiation between the exo and endo N-(bornan-2-yl)- acetamides, and have led to errors by previous workers. Spectral differences leading to unambiguous assignment are discussed in this paper. Trapping of the bornan-2-yl carbenium ion with acetonitrile leads to exo products.

  熔点 熔点为区分外源性和内源性 N-(bornan-2-yl)-乙酰胺提供了一种较差的方法，这也导致了以前的研究人员出现错误。 本文讨论了导致明确分配的光谱差异。 的光谱差异。Bornan-2-yl 碳鎓离子与 乙腈捕获，产生外向产物。
• Synthesis and evaluation of camphor and cytisine-based cyanopyrrolidines as DPP-IV inhibitors for the treatment of type 2 diabetes mellitus
  作者：S.O. Kuranov、I.P. Tsypysheva、M.V. Khvostov、Liana F. Zainullina、S.S. Borisevich、Yu.V. Vakhitova、O.A. Luzina、N.F. Salakhutdinov

  DOI：10.1016/j.bmc.2018.07.018

  日期：2018.8

  In this study, bornyl- and cytisine-based cyanopyrrolidines as potent dipeptidyl peptidase-IV (DPP-IV) inhibitors were synthesised. The in vitro inhibiting activities of bornyl- and cytisine derivatives towards DPP-IV were evaluated. Bornyl-based cyanopyrrolidines were shown to have moderate inhibitory activity with regard to DPP-IV (1.27–15.78 µM). A docking study was performed to elucidate the structure-activity

  在这项研究中，合成了基于冰片和胱氨酸的氰基吡咯烷类作为有效的二肽基肽酶-IV（DPP-IV）抑制剂。在体外bornyl-并朝向DPP-IV金雀花碱衍生物的抑制活性进行了评价。已显示基于硼烷基的氰基吡咯烷对DPP-IV具有中等抑制活性（1.27–15.78 µM）。进行对接研究以阐明获得的化合物的结构-活性关系。在体内的相同化合物的降血糖活性用小鼠口服葡萄糖耐量试验（OGTT）进行评价。证实基于硼烷基的氰基吡咯烷具有良好的降血糖活性。
• Common ligand mimics: thiazolidinediones and rhodanines
  申请人：Yu Lin

  公开号：US20050042674A9

  公开（公告）日：2005-02-24

  The present invention provides common ligand mimics that act as common ligands for a receptor family. The present invention also provides bi-ligands containing these common ligand mimics. Bi-ligands of the invention provide enhanced affinity and/or selectivity of ligand binding to a receptor or receptor family through the synergistic action of the common ligand mimic and specificity ligand which compose the bi-ligand. The present invention also provides combinatorial libraries containing the common ligand mimics and bi-ligands of the invention. Further, the present invention provides methods for manufacturing the common ligand mimics and bi-ligands of the invention and methods for assaying the combinatorial libraries of the invention.

  本发明提供了作为受体家族通用配体的通用配体模拟物。本发明还提供了含有这些通用配体模拟物的双配体。本发明的双配体通过通用配体模拟物和组成双配体的特异性配体的协同作用，提供了对受体或受体家族的配体结合的增强亲和力和/或选择性。本发明还提供了含有通用配体模拟物和本发明的双配体的组合库。此外，本发明还提供了制造通用配体模拟物和本发明的双配体的方法以及检测本发明的组合库的方法。
• "Hydrophobic" binding of water-soluble guests by high-symmetry, chiral hosts. An electron-rich receptor site with a general affinity for quaternary ammonium compounds and electron-deficient .pi. systems
  作者：Michael A. Petti、Timothy J. Shepodd、Richard E. Barrans、Dennis A. Dougherty

  DOI：10.1021/ja00228a036

  日期：1988.9
• Cycloalkyl Indole-2-Carboxylates as Useful Tools for Mapping the "North-Eastern" Region of the Glycine Binding Site Associated with the NMDA Receptor
  作者：Fabrizio Micheli、Romano Di Fabio、Anna M. Capelli、Alfredo Cugola、Ornella Curcuruto、Aldo Feriani、Paola Gastaldi、Giovanni Gaviraghi、Carla Marchioro、Alessandra Orlandi、Alfonso Pozzan、Anna M. Quaglia、Angelo Reggiani、Frank van Amsterdam

  DOI：10.1002/(sici)1521-4184(19993)332:3<73::aid-ardp73>3.0.co;2-5

  日期：1999.3

  A novel series of indole-2-carboxylate analogues of GV 150526 (1) in-which the terminal phenyl ring belonging to the side chain present in the position C-3 has been replaced with a bridged cycloalkyl group was synthesized and evaluated for its pharmacological profile. Modelling studies on this class of novel glycine antagonist allowed us to identify an asymmetric lipophilic pocket present in the "North-Eastern" region of the pharmacophoric model of the glycine binding site associated to the NMDA receptor. Among the derivatives prepared, 3-[2-(1-adamantylaminocarbonyl)ethenyl]-4,6-dichloroindole-2-carboxylic acid 6b and 3-[2(norbornylaminocarbonyl)ethenyl]-4,6-dichloroindole-2-carboxylic acid 61 were found to be antagonists acting at the strychnine-insensitive glycine binding site, showing nanomolar affinity for the glycine binding site (K-i = 63 and 19 nM, respectively), coupled with high glutamate receptor selectivity (IC50 > 10(-5) M at the NMDA, AMPA, KA binding sites) and high in vivo potency after :systemic administration by inhibition of convulsion induced by NMDA in mice.